BLD-2660
- Generic Name
- BLD-2660
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- Blade Therapeutics
- Target Recruit Count
- 120
- Registration Number
- NCT04334460
- Locations
- 🇺🇸
Blade Reseach Site, San Jose, California, United States
🇧🇷Blade Research Site, Vitória, Brazil
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- Blade Therapeutics
- Registration Number
- NCT04244825
- Locations
- 🇬🇧
Blade Research Site, London, United Kingdom
Healthy Volunteer Study Comparing Tablet and Capsule Formulations
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- Blade Therapeutics
- Registration Number
- NCT04001998
- Locations
- 🇦🇺
Scientia Clinical Research, Randwick, New South Wales, Australia
First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Blade Therapeutics
- Target Recruit Count
- 88
- Registration Number
- NCT03559166
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath